# Open-Label, Dose-Escalation Study of 2 to 5 IM Doses of MEDI-524 at 3 mg/kg or 15 mg/kg; Children to be Followed for 90 Days After Their Last Dose of MEDI-524

> **NCT00192478** · PHASE1,PHASE2 · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 217 (actual)

## Conditions studied

- Respiratory Syncytial Virus Infections

## Interventions

- **BIOLOGICAL:** Medi-524

## Key facts

- **NCT ID:** NCT00192478
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-02
- **Primary completion:** 2006-05
- **Final completion:** 2006-08
- **Target enrollment:** 217 (ACTUAL)
- **Last updated:** 2008-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00192478

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00192478, "Open-Label, Dose-Escalation Study of 2 to 5 IM Doses of MEDI-524 at 3 mg/kg or 15 mg/kg; Children to be Followed for 90 Days After Their Last Dose of MEDI-524". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00192478. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*